title: [Large granular lymphocytic leukemia. A rare disease with personalized treatment options].
abstract: BACKGROUND
  Large granular lymphocyte leukemia is rare, mainly chronic disease. The most common complication is neutropenia, but other immune-mediated cytopenia may also occur. There are no unified treatment recommendations and initiation of treatment mainly depends on the severity of the symptoms.
  
  
  OBJECTIVE
  The aim of the authors was to analyze the main steps of the diagnosis and the necessity and outcome of treatment in their patients diagnosed with large granular lymphocyte leukaemia.
  
  
  METHODS
  The authors retrospectively analyzed the data of 17 large granular lymphocyte leukemia patients.
  
  
  RESULTS
  Of the 17 patients, 7 patients required treatment because of transfusion dependent anemia (4 patients) or neutropenia (3 patients). In 4 patients corticosteroid was given (supplemented with cyclosporine in one patients), while the other patients received anti-CD52 (one patient), low dose methotrexate (one patient) and combined chemotherapy (one patient). Five patients achieved partial response, and two patients died in sepsis.
  
  
  CONCLUSIONS
  In this cohort only a smaller proportion of patients required therapy. Immunosuppression can be successful, but the effect in most cases was temporary. The most serious complication was sepsis, which is associated with a significant risk of mortality in cases with neutropenia.
authors.affiliation: Szegedi Tudományegyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika és Kardiológiai Központ, Hematológiai Osztály Szeged Korányi fasor 6. 6720.
authors.forename: Nóra
authors.initials: N
authors.lastname: Adamkovich
authors.affiliation: Dr. Bugyi István Kórház Onkológiai Osztály Szentes.
authors.forename: Mihály
authors.initials: M
authors.lastname: Kispál
authors.affiliation: Szegedi Tudományegyetem, Általános Orvostudományi Kar Daganatpatológiai és Molekuláris Diagnosztikai Laboratórium Szeged.
authors.forename: László
authors.initials: L
authors.lastname: Krenács
authors.affiliation: Szegedi Tudományegyetem, Általános Orvostudományi Kar Daganatpatológiai és Molekuláris Diagnosztikai Laboratórium Szeged.
authors.forename: Enikő
authors.initials: E
authors.lastname: Bagdi
authors.affiliation: Szegedi Tudományegyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika és Kardiológiai Központ, Hematológiai Osztály Szeged Korányi fasor 6. 6720.
authors.forename: Zita
authors.initials: Z
authors.lastname: Borbényi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D054066:Leukemia, Large Granular Lymphocytic / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods; D009503:Neutropenia / Q000139:chemically induced* / Q000150:complications; D057285:Precision Medicine / Q000379:methods; D035583:Rare Diseases / Q000175:diagnosis / Q000188:drug therapy; D012189:Retrospective Studies; D018805:Sepsis / Q000209:etiology / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D015703:Antigens, CD; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate
keywords: immunosuppression; immunszuppresszió; large granular lymphocyte leukemia; nagy granulált lymphocytás leukaemia; neutropenia